DNA Link, Inc.

Equities

A127120

KR7127120004

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-05-06 pm EDT 5-day change 1st Jan Change
2,900 KRW 0.00% Intraday chart for DNA Link, Inc. +17.41% -0.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd. CI
DNA Link, Inc. announced that it has received KRW 5.000000096 billion in funding from Orbitech Co., Ltd. CI
DNA Link, Inc. announced that it expects to receive KRW 15 billion in funding from Deokcheon Co., Ltd. and other investors CI
DNA Link, Inc. announced that it expects to receive KRW 5.000001012 billion in funding from Orbitech Co., Ltd. CI
SomaLogic Inc. and DNA Link Partners to Bring the 7,000-Plex Somascan Platform to the Fast-Growing Asia-Pacific Proteomics Market CI
DNA Link, Inc. cancelled the transaction announced on May 2, 2023 CI
DNA Link, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
DNA Link to Raise 20 Billion Won From Share Sale; Shares Rise 3% MT
DNA Link, Inc. announced that it expects to receive KRW 20.00000167 billion in funding CI
DNA Link, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
DNA Link, Inc. entered into agreement to acquire 40% stake in National Bitumen Corporation for KRW9.6 billion. CI
Entermedia Co.,Ltd. announced that it has received KRW 6 billion in funding from DNA Link, Inc. CI
DNA Link, Inc. announced that it has received KRW 2.1 billion in funding from Entermedia Co.,Ltd. CI
Entermedia Co.,Ltd. announced that it expects to receive KRW 6 billion in funding CI
DNA Link, Inc. announced that it expects to receive KRW 2.1 billion in funding from Entermedia Co.,Ltd. CI
DNA Link, Inc. agreed to acquire Entermedia Co.,Ltd. for KRW 4.9 billion. CI
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test act the Point of Care CI
DNA Link, Inc. announced that it has received KRW 7 billion in funding from Shinhan Capital Co., Ltd. CI
DNA Link, Inc. announced that it expects to receive KRW 8 billion in funding from Shinhan Capital Co., Ltd. CI
DNA Link, Inc. announced that it has received KRW 2.1 billion in funding from Balancers Co., Ltd., Eugene Investment & Securities Co., Ltd. CI
DNA Link, Inc. announced that it expects to receive KRW 4 billion in funding from Balancers Co., Ltd., Eugene Investment & Securities Co.,Ltd. CI
DNA Link, Inc. announced that it has received KRW 7 billion in funding from Synergy IB Investment Co., Ltd. CI
DNA Link, Inc. completed the acquisition of L&C Bio Co., Ltd. from Hyungseok Choi and Myunghee Jung. CI
DNA Link, Inc. announced that it expects to receive KRW 7 billion in funding from Synergy IB Investment Co., Ltd. CI
DNA Link, Inc. agreed to acquire L&C Bio Co., Ltd. from Hyungseok Choi and Myunghee Jung for KRW 3.5 billion. CI
Chart DNA Link, Inc.
More charts
DNA LINK, INC. is a Korea-based company engaged in the genetics research business. The Company provides genome biomarkers excavation products through integrated genomic analysis and integrated clinical information analysis including high-quality data products according to genomic analysis, interpretation of analysis results, and technologies of molecular diagnostic kit production under the brand name of enhanced genome integration system (EGIS). The Company also provides personal genome analysis service products under the brand name of deoxyribonucleic acid personalized services (DNAGPS).
More about the company
  1. Stock Market
  2. Equities
  3. A127120 Stock
  4. News DNA Link, Inc.
  5. DNA Link to Raise 20 Billion Won From Share Sale; Shares Rise 3%
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW